In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

At Regen Med Meeting, Cardio3, Others Grapple With Complex Market

Executive Summary

At the recent European Advanced Therapies Investor Day in London, pharma and medtech attendees touted the need for open minds and innovative approaches to developing cell therapies.

You may also be interested in...



The Regenerative Market Brings The Future Closer

A clear sign the regenerative medicine and therapy market is making considerable progress comes from the amount of investor funding pouring into the space, and although a lot of the technology is still spoken about in the future tense, a variety of new companies are bringing the future much closer. An additional hallmark of the market is the role device companies are finding for themselves in an industry primarily lead by pharmaceutical businesses.

Argos Aims To Automate Cell-Based Cancer Therapy

Eventually, someone is going to have clinical and commercial success with a personalized cancer therapy. Learning from the mistakes of Dendreon and others, Argos Therapeutics expects to be first, and automation is its key.

US Election 2020: Device Firms Spending Twice As Much On Biden Than On Trump

Just five weeks before the US election, a Medtech Insight analysis shows medical device companies are spending more on Democrat Joe Biden’s campaign than on Republican Donald Trump’s.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132115

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel